
The US Food and Drug Administration (FDA) granted a Fast Track designation to InflaRx’s (NASDAQ:IFRX) lead candidate Vilobelimab for the treatment of ulcerative Pyoderma Gangrenosum (PG).
The FDA grant was supported by the positive data readout in pyoderma gangrenosum (PG) from its Phase 2a open-label dose-escalation study.